Patrys (ASX:PAB) has taken significant steps toward advancing a potential new treatment for delirium into human clinical trials, including manufacturing and regulatory preparations for its experimental drug candidate RLS-2201. …
Patrys moves toward first human trial for injectable delirium therapy
March 12, 2026 Australian Biotech
Latest Video
New Stories
-
Australian company secures European approval for rare disease treatment
August 26, 2026 - - Latest News -
Australia cannot deliver meaningful change until the levers of power are rebalanced
August 26, 2026 - - Latest News -
Insurers warn cut could hit Australians most likely to need cancer care
August 25, 2026 - - Latest News -
Australian study finds maternal RSV vaccination offers strong protection for infants
August 25, 2026 - - Latest News -
Acrux brings experienced clinical leader aboard to advance testosterone program
August 24, 2026 - - Australian Biotech -
Avecho moves to deepen global partnering push as CBD insomnia program advances
August 24, 2026 - - Australian Biotech -
July recommendations across oncology, rare disease and chronic care
August 24, 2026 - - Latest News